FN-1501
- Generic Name
- FN-1501
- Brand Names
- Cellcept, Myfenax, CellCept, Mycophenolate mofetil Teva, Myclausen
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25N9O
- CAS Number
- 1429515-59-2
- Unique Ingredient Identifier
- 6MC966B505
- Background
Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is markete...
- Indication
Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old. Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy. Other off-l...
- Associated Conditions
- Transplanted Organ Rejection
- Associated Therapies
- -
Treatment Strategies in IgG4-RD Patients With Re-elevation of Serum IgG4 Level During Maintenance Remission Period
- Conditions
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 108
- Registration Number
- NCT05974683
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Chinese SLE Treatment And Research Group
- Target Recruit Count
- 220
- Registration Number
- NCT05916781
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT05907746
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-04-19
- Target Recruit Count
- 46
- Registration Number
- NCT05843968
- Locations
- 🇨🇳
Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Target Recruit Count
- 38
- Registration Number
- NCT05807932
- Locations
- 🇩🇪
Universitätsklinikum Frankfurt Medizinische Klinik II, Frankfurt, Germany
🇩🇪Universitätsklinikum Jena - Klinik für Innere Medizin II, Jena, Germany
🇩🇪Universitätsklinikum Aachen - Med. Klinik IV, Aachen, NRW, Germany
Allo HSCT Using RIC and PTCy for Hematological Diseases
- Conditions
- Interventions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 56
- Registration Number
- NCT05805605
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement
- Conditions
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05789017
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
- Conditions
- Interventions
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2023-10-16
- Target Recruit Count
- 35
- Registration Number
- NCT05785065
- Locations
- 🇨🇦
St-Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
🇨🇦Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada
🇨🇦Jewish General Hospital - CIUSSS-COMTL, Montreal, Quebec, Canada
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05736419
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen (Consent only), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey, United States
Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Fen Li
- Target Recruit Count
- 30
- Registration Number
- NCT05666336
- Locations
- 🇨🇳
Department of Rheumatology and Immunology, Xiangya Second Hospital, Central South University, Changsha, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.